Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (332)	5/6/1999 4:43:00 PM
From: tommysdad	Read Replies (2) \| Respond to of 399

<<There has never been a combinatorial chemistry molecule that reached the clinic.>> Probably not true. Both Merck and Lilly have been reported to have put "a combinatorial chemistry molecule" into the clinic. They just don't announce such things. Note that the press release you link is from Arqule -- Roche would not have made an announcement about a preclinical compound, or even an IND. I'm actually worried that ARQL would choose to announce such a thing. An IND, yes, but "selected for development"? Not that big a deal.